|
Type |
Publikáció |
| 3 |
Napló |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 12 |
Napló |
Owens LC, Fleming RA, Restino MS, Cruz JM, Hurd DD.
Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion.
Am J Health-Syst Pharm 1997 ; 54: 683-686. |
| 36 |
Napló |
Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Am J Health-Syst Pharm 1995 ; 52: 2423-2426. |
| 59 |
Napló |
Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 73 |
Napló |
Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159. |
| 81 |
Napló |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Napló |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Napló |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
Napló |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Napló |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 198 |
Napló |
Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 201 |
Napló |
Thompson DF, Allen LV, Stiles ML.
Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2530-2531. |
| 215 |
Napló |
Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 244 |
Napló |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 248 |
Napló |
Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304. |
| 249 |
Napló |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Napló |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 253 |
Napló |
Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528. |
| 256 |
Napló |
Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA.
Stability of fluconazole in commonly used intravenous antibiotic solutions.
Am J Hosp Pharm 1993 ; 50: 1206-1208. |
| 265 |
Napló |
Trissel LA.
Amphotericin B does not mix with fat emulsion.
Am J Health-Syst Pharm 1995 ; 52: 1463-1464. |
| 266 |
Napló |
Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
| 270 |
Napló |
Heide PE.
Precipitation of amphotericin B from IV fat emulsion.
Am J Health-Syst Pharm 1997 ; 54: 1449. |
| 280 |
Napló |
Allen LV, Stiles ML, Prince SJ, Sylvestri MF.
Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2427-2433. |
| 283 |
Napló |
Lee MD, Hess MM, Boucher BA, Apple AM.
Stability of amphotericin B in 5% dextrose injection stored at 4 or 25°C for 120 hours.
Am J Hosp Pharm 1994 ; 51: 394-396. |
| 285 |
Napló |
Elmore RL, Contois ME, Kelly J, Noe A, Poirier A.
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.
Clin Ther 1996 ; 18: 246-255. |
| 299 |
Napló |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 |
Napló |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Napló |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 |
Napló |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 334 |
Napló |
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992. |
| 335 |
Napló |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 337 |
Napló |
Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533. |
| 435 |
Napló |
Wiest DB, Maish WA, Garner SS, El-Chaar GM.
Stability of amphotericin B in four concentrations of dextrose injection.
Am J Hosp Pharm 1991 ; 48: 2430-2433. |
| 436 |
Napló |
Mitrano FP, Outman WR, Baptista RJ, Palombo JD.
Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4°C for 35 days.
Am J Hosp Pharm 1991 ; 48: 2635-2637. |
| 439 |
Napló |
Kintzel PE, Kennedy PE.
Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line.
Am J Hosp Pharm 1991 ; 48: 283-285. |
| 479 |
Napló |
Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 492 |
Napló |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 |
Napló |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 497 |
Napló |
Kintzel PE, Kennedy PE.
Stability of amphotericin B in 5% dextrose injection at 25°C.
Am J Hosp Pharm 1991 ; 48: 1681. |
| 604 |
Laboratórium |
Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998 |
| 682 |
Napló |
Raymond GG, Davis RL.
Physical compatibility and chemical stability of amphotericin B in combination with magnesium sulfate in 5% dextrose injection.
Ann Pharmacotherapy 1991 ; 25: 123-126. |
| 793 |
Napló |
Ranch?re JY, Latour JF, Fuhrmann C, Lagallarde C, Loreuil F.
Amphotericin B intralipid formulation: stability and particule size.
J Antimicrob Chemother 1996 ; 37: 1165-1169. |
| 892 |
Napló |
Kintzel PE, Smith GH.
Practical guidelines for preparing and administering amphotericin B.
Am J Hosp Pharm 1992 ; 49: 1156-1164. |
| 905 |
Napló |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 984 |
Napló |
Ericsson O, Hallmen AC, Wikstrom I.
Amphotericin B is incompatible with lipid emulsions.
Ann Pharmacotherapy 1996 ; 30: 298. |
| 1057 |
Napló |
Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1135 |
Napló |
Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077. |
| 1172 |
Napló |
Jurgens RW, DeLuca PP, Papadimitriou D.
Compatibility of amphotericin B with certain large-volume parenterals.
Am J Hosp Pharm 1981 ; 38: 377-378. |
| 1201 |
Napló |
Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.
Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.
Am J Hosp Pharm 1981 ; 38: 1919-1922. |
| 1410 |
Napló |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 |
Napló |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1423 |
Napló |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1498 |
Napló |
Cleary JD.
Amphotericin B formulated in a lipid emulsion.
Ann Pharmacotherapy 1996 ; 30: 409-412. |
| 1611 |
Napló |
Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506. |
| 1625 |
Napló |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1703 |
Napló |
Schuster F, Bernard R.
Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln.
Krankenhauspharmazie 1995 ; 16: 101-103. |
| 1712 |
Napló |
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
Napló |
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
Napló |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1754 |
Napló |
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244. |
| 1803 |
Napló |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1907 |
Napló |
Burger DE, Caldwell JW.
Sustaining treatment of coccidioidal meningitidis by extending the stability of amphotericin B.
Hosp Pharm 2004 ; 39: 554-557. |
| 1925 |
Napló |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1953 |
Napló |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1982 |
Napló |
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2043 |
Napló |
Walker S, Tailor SAA, Lee M, Louie L, Louie M, Simor AE.
Amphotericin B in lipid emulsion : stability, compatibility, and in vitro antifungal activity.
Antimicrob Agents Chemother 1998 ; 42: 762-766. |
| 2090 |
Napló |
Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196. |
| 2247 |
Napló |
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278. |
| 2262 |
Napló |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 2269 |
Napló |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3152 |
Napló |
Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
| 3216 |
Napló |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 |
Napló |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3254 |
Napló |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3332 |
Laboratórium |
Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012 |
| 3408 |
Napló |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3539 |
Laboratórium |
Bivalirudin (Angiox®) - Summary of Product Characteristics.
The Medecines Company 2013 |
| 3549 |
Laboratórium |
Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012 |
| 3560 |
Laboratórium |
Linezolid (Zyvox®) - Summary of Product Characteristics
Pharmacia 2013 |
| 3564 |
Laboratórium |
Rocuronium B Braun - Résumé des caractéristiques du produit.
B Braun 2012 |
| 3585 |
Laboratórium |
Benzylpenicillin sodium - Summary of Product Characteristics
Genus Pharmaceuticals 2008 |
| 3591 |
Laboratórium |
Amphotericine B (Fungizone®) - Résumé des caractéristiques du produit
Bristol Myers Squibb 2011 |
| 3638 |
Laboratórium |
Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics
Hospira 2010 |
| 3644 |
Laboratórium |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3662 |
Laboratórium |
Foscavir (Foscarnet®) - Summary of Product Characteristics
Clinigen 2014 |
| 3766 |
Napló |
Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3767 |
Napló |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3791 |
Poszter |
Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014 |
| 3828 |
Poszter |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
Poszter |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 3869 |
Napló |
Sun P, Chen J, Zhang Z, Gao X, Chen P, Li X.
Influence of 5% dextrose volume on amphotericin B deoxycholate preparation
J Pharm Pharmacol 2016 ; 68: 433-438. |
| 3871 |
Poszter |
Soussi M.A, Soualah-alila R, jenene F, Lazreg O, Razgallah Khrouf M.
Peut-on administrer le céfotaxime en Y avec d'autres médicaments injectables ?
Synprefh Congress Clermont Ferrand, France 2016 |
| 3883 |
Laboratórium |
Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016 |
| 3968 |
Laboratórium |
Ringer lactate - Résumé des Caractéristiques du Produit
Fresenius Kabi 2015 |
| 4055 |
Napló |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4145 |
Napló |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4528 |
Napló |
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61 |
| 4543 |
Napló |
Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295. |
| 4650 |
Laboratórium |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
